NYMX - Nymox Pharmaceutical Corporation
| Previous Close | 4.19 |
| Open | 4.18 |
| Bid | 4.29 x 100 |
| Ask | 4.30 x 6600 |
| Day's Range | 4.10 - 4.35 |
| 52 Week Range | 3.00 - 5.10 |
| Volume | 55,683 |
| Avg. Volume | 140,746 |
| Market Cap | 245.992M |
| Beta | 0.44 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.25 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.25 |
- Simply Wall St.•10 days ago
Should You Worry About Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) CEO Pay?
Leading Nymox Pharmaceutical Corporation (NASDAQ:NYMX) as the CEO, Paul Averback took the company to a valuation of US$236.27M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...
- GlobeNewswire•11 days ago
Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors
HASBROUCK HEIGHTS, N.J., April 12, 2018-- Nymox Pharmaceutical Corporation is pleased to announce today that the Company has successfully secured $16.25 million in new equity capital with several professional ...
- GlobeNewswire•13 days ago
New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology
HASBROUCK HEIGHTS, N.J., April 10, 2018-- A new online published commentary about Nymox’ s Fexapotide 2018 clinical trial results publication in World Journal of Urology has newly appeared today on UroToday ...
- Simply Wall St.•last month
Should You Have Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) In Your Portfolio?
For Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. NYMX is exposedRead More...
- GlobeNewswire•2 months ago
Symposium and Panel Discussion on Nymox's Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3
HASBROUCK HEIGHTS, N.J., March 01, 2018-- Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological ...
- Simply Wall St.•2 months ago
Interested In Nymox Pharmaceutical Corporation (NASDAQ:NYMX)? Here’s What Its Recent Performance Looks Like
Today I will take a look at Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX) most recent earnings update (30 September 2017) and compare these latest figures against its performance over the past fewRead More...
- GlobeNewswire•3 months ago
Nymox Announces US NDA for Fexapotide for BPH
HASBROUCK HEIGHTS, N.J., Feb. 05, 2018-- Nymox Pharmaceutical Corporation announced today that the Company will submit a New Drug Application for Fexapotide Triflutate for the treatment of BPH in the US. ...
- GlobeNewswire•3 months ago
Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology
HASBROUCK HEIGHTS, N.J., Jan. 30, 2018-- Nymox Pharmaceutical Corporation reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published ...
- Capital Cube•5 months ago
Nymox Pharmaceutical Corp. :NYMX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis Nymox Pharmaceutical Corp. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Nymox Pharmaceutical Corp. – Abbott Laboratories, Eli Lilly and Company, Quest Diagnostics Incorporated, Pfizer Inc., Johnson & Johnson and Sophiris Bio Inc. (ABT-US, LLY-US, DGX-US, PFE-US, JNJ-US and ... Read more (Read more...)
- Simply Wall St.•6 months ago
Nymox Pharmaceutical Corporation (NYMX): How Does It Impact Your Portfolio?
If you are a shareholder in Nymox Pharmaceutical Corporation’s (NASDAQ:NYMX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
